TNFSF13B rs9514828 C>T 多态性与系统性红斑狼疮患者的动脉粥样硬化发病率和治疗效果有关。

IF 5.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Biologics : Targets & Therapy Pub Date : 2024-05-03 eCollection Date: 2024-01-01 DOI:10.2147/BTT.S452792
Desi Reski Fajar, Tina Rostinawati, Laniyati Hamijoyo, Edhyana Sahiratmadja, Riezki Amalia, Melisa Intan Barliana
{"title":"TNFSF13B rs9514828 C>T 多态性与系统性红斑狼疮患者的动脉粥样硬化发病率和治疗效果有关。","authors":"Desi Reski Fajar, Tina Rostinawati, Laniyati Hamijoyo, Edhyana Sahiratmadja, Riezki Amalia, Melisa Intan Barliana","doi":"10.2147/BTT.S452792","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the <i>TNFSF13B</i> gene has been found to be linked with SLE events. This study aimed to analyze the association between single nucleotide polymorphisms of the <i>TNFSF13B</i> rs9514828 with incidence of atherosclerosis and therapeutic outcomes in patients with SLE.</p><p><strong>Patients and methods: </strong>This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The <i>TNFSF13B</i> gene polymorphism was evaluated using polymerase chain reaction followed by sequencing. The lupus low disease activity state (LLDAS) criteria were used to measure the therapeutic outcomes. Statistical analysis was conducted using binary logistic regression.</p><p><strong>Results: </strong>The genetic variations of <i>TNFSF13B</i> rs9514828 were CC = 35, CT = 41, and TT = 8. There was an association between <i>TNFSF13B</i> rs9514828 C>T polymorphism in patients with SLE with and without atherosclerosis (p = 0.03; odds ratio (OR) 4.72, 95% confidence interval [CI] 1.22-18.37). Furthermore, the <i>TNFSF13B</i> rs9514828 C>T polymorphism had association with the therapeutic outcomes of patients with SLE who manifested with LLDAS (p = 0.00; OR 7.58, 95% CI 2.61-21.99).</p><p><strong>Conclusion: </strong>The association of <i>TNFSF13B</i> rs9514828 C>T polymorphism and incidence of atherosclerosis as well as the therapeutic outcomes in patients with SLE indicate the potential utility of the gene variation as screening tool to employ personalized medicine to undertake preventive measures in order to prevent atherosclerosis and to predict a poor prognosis in SLE patient.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"18 ","pages":"95-106"},"PeriodicalIF":5.3000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075687/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>TNFSF13B</i> rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus.\",\"authors\":\"Desi Reski Fajar, Tina Rostinawati, Laniyati Hamijoyo, Edhyana Sahiratmadja, Riezki Amalia, Melisa Intan Barliana\",\"doi\":\"10.2147/BTT.S452792\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the <i>TNFSF13B</i> gene has been found to be linked with SLE events. This study aimed to analyze the association between single nucleotide polymorphisms of the <i>TNFSF13B</i> rs9514828 with incidence of atherosclerosis and therapeutic outcomes in patients with SLE.</p><p><strong>Patients and methods: </strong>This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The <i>TNFSF13B</i> gene polymorphism was evaluated using polymerase chain reaction followed by sequencing. The lupus low disease activity state (LLDAS) criteria were used to measure the therapeutic outcomes. Statistical analysis was conducted using binary logistic regression.</p><p><strong>Results: </strong>The genetic variations of <i>TNFSF13B</i> rs9514828 were CC = 35, CT = 41, and TT = 8. There was an association between <i>TNFSF13B</i> rs9514828 C>T polymorphism in patients with SLE with and without atherosclerosis (p = 0.03; odds ratio (OR) 4.72, 95% confidence interval [CI] 1.22-18.37). Furthermore, the <i>TNFSF13B</i> rs9514828 C>T polymorphism had association with the therapeutic outcomes of patients with SLE who manifested with LLDAS (p = 0.00; OR 7.58, 95% CI 2.61-21.99).</p><p><strong>Conclusion: </strong>The association of <i>TNFSF13B</i> rs9514828 C>T polymorphism and incidence of atherosclerosis as well as the therapeutic outcomes in patients with SLE indicate the potential utility of the gene variation as screening tool to employ personalized medicine to undertake preventive measures in order to prevent atherosclerosis and to predict a poor prognosis in SLE patient.</p>\",\"PeriodicalId\":9025,\"journal\":{\"name\":\"Biologics : Targets & Therapy\",\"volume\":\"18 \",\"pages\":\"95-106\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075687/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biologics : Targets & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/BTT.S452792\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics : Targets & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BTT.S452792","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:系统性红斑狼疮(SLE)是一种复杂的自身免疫性疾病,具有多种临床表现。器官受累会加重系统性红斑狼疮患者的病情,并导致动脉粥样硬化等合并症。最近,人们发现 TNFSF13B 基因与系统性红斑狼疮事件有关。本研究旨在分析 TNFSF13B rs9514828 单核苷酸多态性与系统性红斑狼疮患者动脉粥样硬化发病率和治疗效果之间的关系:这项病例对照研究纳入了84名系统性红斑狼疮患者,其中21名系统性红斑狼疮患者伴有动脉粥样硬化,63名系统性红斑狼疮患者无动脉粥样硬化。采用酶联免疫吸附法对白细胞介素-6和干扰素γ的水平进行了定量分析。采用聚合酶链式反应和测序法评估了 TNFSF13B 基因的多态性。狼疮低疾病活动状态(LLDAS)标准用于衡量治疗效果。统计分析采用二元逻辑回归法:TNFSF13B rs9514828 的基因变异为 CC = 35、CT = 41 和 TT = 8。TNFSF13B rs9514828 C>T 多态性在伴有或不伴有动脉粥样硬化的系统性红斑狼疮患者中存在关联(P = 0.03;比值比 (OR) 4.72,95% 置信区间 [CI] 1.22-18.37)。此外,TNFSF13B rs9514828 C>T 多态性与表现为 LLDAS 的系统性红斑狼疮患者的治疗效果有关(P = 0.00;OR 7.58,95% CI 2.61-21.99):TNFSF13B rs9514828 C>T多态性与系统性红斑狼疮患者动脉粥样硬化的发病率和治疗效果有关,这表明该基因变异可作为筛查工具用于个性化医疗,采取预防措施以防止动脉粥样硬化,并预测系统性红斑狼疮患者的不良预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
TNFSF13B rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus.

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the TNFSF13B gene has been found to be linked with SLE events. This study aimed to analyze the association between single nucleotide polymorphisms of the TNFSF13B rs9514828 with incidence of atherosclerosis and therapeutic outcomes in patients with SLE.

Patients and methods: This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The TNFSF13B gene polymorphism was evaluated using polymerase chain reaction followed by sequencing. The lupus low disease activity state (LLDAS) criteria were used to measure the therapeutic outcomes. Statistical analysis was conducted using binary logistic regression.

Results: The genetic variations of TNFSF13B rs9514828 were CC = 35, CT = 41, and TT = 8. There was an association between TNFSF13B rs9514828 C>T polymorphism in patients with SLE with and without atherosclerosis (p = 0.03; odds ratio (OR) 4.72, 95% confidence interval [CI] 1.22-18.37). Furthermore, the TNFSF13B rs9514828 C>T polymorphism had association with the therapeutic outcomes of patients with SLE who manifested with LLDAS (p = 0.00; OR 7.58, 95% CI 2.61-21.99).

Conclusion: The association of TNFSF13B rs9514828 C>T polymorphism and incidence of atherosclerosis as well as the therapeutic outcomes in patients with SLE indicate the potential utility of the gene variation as screening tool to employ personalized medicine to undertake preventive measures in order to prevent atherosclerosis and to predict a poor prognosis in SLE patient.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biologics : Targets & Therapy
Biologics : Targets & Therapy MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
8.30
自引率
0.00%
发文量
22
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信